WO2007070907A3 - Therapeutic compositions - Google Patents

Therapeutic compositions Download PDF

Info

Publication number
WO2007070907A3
WO2007070907A3 PCT/AT2006/000530 AT2006000530W WO2007070907A3 WO 2007070907 A3 WO2007070907 A3 WO 2007070907A3 AT 2006000530 W AT2006000530 W AT 2006000530W WO 2007070907 A3 WO2007070907 A3 WO 2007070907A3
Authority
WO
WIPO (PCT)
Prior art keywords
seq
therapeutic compositions
leukemia
orf15δ
hectd1δ
Prior art date
Application number
PCT/AT2006/000530
Other languages
French (fr)
Other versions
WO2007070907A2 (en
Inventor
Alexander Dohnal
Thomas Felzmann
Renate Panzer-Gruemayer
Original Assignee
St Anna Kinderkrebsforschung
Austria Wirtschaftsserv Gmbh
Alexander Dohnal
Thomas Felzmann
Renate Panzer-Gruemayer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Anna Kinderkrebsforschung, Austria Wirtschaftsserv Gmbh, Alexander Dohnal, Thomas Felzmann, Renate Panzer-Gruemayer filed Critical St Anna Kinderkrebsforschung
Publication of WO2007070907A2 publication Critical patent/WO2007070907A2/en
Publication of WO2007070907A3 publication Critical patent/WO2007070907A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composition for the treatment of leukemia, in particular of acute lymphoblastic leukemia, comprising antigen-presenting cells loaded with a protein or an immunogenic isoform-specific fragment thereof selected from the group consisting of HECTD1Δ (SEQ ID No. 1), CX-ORF15Δ (SEQ ID No. 2), hCAP-EΔ (SEQ ID No. 3) and combinations thereof.
PCT/AT2006/000530 2005-12-21 2006-12-21 Therapeutic compositions WO2007070907A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT20512005 2005-12-21
ATA2051/2005 2005-12-21

Publications (2)

Publication Number Publication Date
WO2007070907A2 WO2007070907A2 (en) 2007-06-28
WO2007070907A3 true WO2007070907A3 (en) 2007-10-04

Family

ID=37758639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2006/000530 WO2007070907A2 (en) 2005-12-21 2006-12-21 Therapeutic compositions

Country Status (1)

Country Link
WO (1) WO2007070907A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2828209A1 (en) * 2001-08-01 2003-02-07 Cytomics Systems New nucleic acid encoding HECT-domain polypeptides, useful e.g. for treatment of cancer or inflammation, also new proteins, antibodies and modulators
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
WO2003072068A2 (en) * 2002-02-27 2003-09-04 University Of South Carolina Targeted immunotherapy of acute lymphoblastic leukemia (all)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
FR2828209A1 (en) * 2001-08-01 2003-02-07 Cytomics Systems New nucleic acid encoding HECT-domain polypeptides, useful e.g. for treatment of cancer or inflammation, also new proteins, antibodies and modulators
WO2003072068A2 (en) * 2002-02-27 2003-09-04 University Of South Carolina Targeted immunotherapy of acute lymphoblastic leukemia (all)

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHEN YT, SCANLAN MJ, OBATA Y, OLD LJ: "Principles and practice of biologic therapy of cancer, 3rd ed." Chapter 16.7: "Identification of human tumor antigens by serological expression cloning (SEREX)", 2000, LIPPINCOTT, WILLIAMS, AND WILKINS, PHILADELPHIA PA, XP001536304 *
DATABASE EMBL [online] 7 March 2006 (2006-03-07), DOHNAL,A.M., PANZER-GRUEMAYER,R.E.: "Anti-leukemia-specific humoral immune response in children with T- lineage acute lymphoblastic leukemia.", XP002431589, retrieved from EBI accession no. Q2KQ74 *
DATABASE SEREX [online] Ludwig Institute for Cancer Research; 9 June 2003 (2003-06-09), XP002431588, retrieved from HTTP://WWW2.LICR.ORG/CANCERIMMUNOMEDB/SHOWGENE.PHP?GENE=ACTR5 *
HOUTENBOS ILSE ET AL: "Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation.", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 52, no. 7, July 2003 (2003-07-01), pages 455 - 462, XP009083043, ISSN: 0340-7004 *
KOKHAEI P ET AL: "Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL.", LEUKEMIA (BASINGSTOKE), vol. 17, no. 5, May 2003 (2003-05-01), pages 894 - 899, XP009083041, ISSN: 0887-6924 *
LING MIN ET AL: "Prevalence of antibodies against proteins derived from leukemia cells in patients with chronic myeloid leukemia", BLOOD, vol. 92, no. 12, 15 December 1998 (1998-12-15), pages 4764 - 4770, XP009083024, ISSN: 0006-4971 *
MAYORDOMO JOSE I ET AL: "Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines", STEM CELLS (MIAMISBURG), vol. 15, no. 2, 1997, pages 94 - 103, XP009083060, ISSN: 1066-5099 *
OELKE M ET AL: "Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 6, no. 5, May 2000 (2000-05-01), pages 1997 - 2005, XP002352660, ISSN: 1078-0432 *
PREUSS KLAUS-DIETER ET AL: "Analysis of the B-cell repertoire against antigens expressed by human neoplasms.", IMMUNOLOGICAL REVIEWS, vol. 188, October 2002 (2002-10-01), pages 43 - 50, XP002431513, ISSN: 0105-2896 *

Also Published As

Publication number Publication date
WO2007070907A2 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
WO2006074051A3 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
WO2004060460A3 (en) Medical devices with cutting element.
WO2005011592A3 (en) Substituted indazole-o-glucosides
AU2002342091A1 (en) Silicone priming compositions, articles and methods_____________
AU2003273276A8 (en) Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
WO2005012243A3 (en) Substituted indole-o-glucosides
WO2007067682A3 (en) In vivo cell surface engineering
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2002076499A3 (en) Combination treatment of pancreatic cancer
WO2005030797A3 (en) Melanocortin receptor agonists
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2002024234A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2006042230A8 (en) Medical devices and methods of making the same
WO2004084950A3 (en) Cell targeting methods and compositions
WO2007053512A3 (en) Novel protein transduction domains and uses therefor
SG167670A1 (en) Aminocyclohexyl ether compounds and uses thereof
WO2004096842A3 (en) Sars virus nucleotide and amino acid sequences and uses thereof
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
WO2009025116A1 (en) Cdh3 peptide and medicinal agent comprising the same
MXPA02012249A (en) Peptides, compositions and methods for the treatment of burkholderia cepacia.
WO2005094761A8 (en) Hair treatment compositions comprising a disaccharide, a di-acid and a source of ammonium ions
WO2004098536A3 (en) Anti-viral activity of cathelicidin peptides
WO2007067795A3 (en) Methods for identifying and targeting tumor stem cells based on nuclear morphology
AU2003233222A1 (en) Aqueous polyurethane preparations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06827960

Country of ref document: EP

Kind code of ref document: A2